Salvage therapies following CAR T-cell therapy failure
| . | HGBL (N = 40)∗ . | DLBCL (N = 167)∗ . |
|---|---|---|
| No salvage treatment, n (%) | 8 | 29 |
| Salvage treatment, n (%) | 32 | 138 |
| First subsequent treatment after CAR T-cell therapy failure, n (%)† | ||
| Bispecific antibody | 11 (34.4) | 40 (29) |
| Anti-CD19 antibody-drug conjugate ± BTKi or lenalidomide | 0 (0) | 9 (6.5) |
| Polatuzumab-based regimens | 4 (12.5) | 25 (18.2) |
| RT | 0 (0) | 11 (7.9) |
| Chemo | 9 (28.1) | 26 (18.8) |
| Others (BTKi, IMiDs, CPI, anti-ROR1) | 8 (25) | 27 (19.6) |
| Bispecific antibody as first or subsequent salvage therapy after CAR T-cell therapy failure, n (%)† | 15 (46.9) | 62 (44.9) |
| No. of treatment lines after CAR T-cell therapy failure, n (%)† | ||
| 1 | 25 (78.1) | 79 (57.2) |
| >1 | 7 (21.9) | 59 (42.8) |
| AlloSCT after CAR T-cell therapy failure, n (%)† | 1 (3.1) | 24 (17.4) |
| . | HGBL (N = 40)∗ . | DLBCL (N = 167)∗ . |
|---|---|---|
| No salvage treatment, n (%) | 8 | 29 |
| Salvage treatment, n (%) | 32 | 138 |
| First subsequent treatment after CAR T-cell therapy failure, n (%)† | ||
| Bispecific antibody | 11 (34.4) | 40 (29) |
| Anti-CD19 antibody-drug conjugate ± BTKi or lenalidomide | 0 (0) | 9 (6.5) |
| Polatuzumab-based regimens | 4 (12.5) | 25 (18.2) |
| RT | 0 (0) | 11 (7.9) |
| Chemo | 9 (28.1) | 26 (18.8) |
| Others (BTKi, IMiDs, CPI, anti-ROR1) | 8 (25) | 27 (19.6) |
| Bispecific antibody as first or subsequent salvage therapy after CAR T-cell therapy failure, n (%)† | 15 (46.9) | 62 (44.9) |
| No. of treatment lines after CAR T-cell therapy failure, n (%)† | ||
| 1 | 25 (78.1) | 79 (57.2) |
| >1 | 7 (21.9) | 59 (42.8) |
| AlloSCT after CAR T-cell therapy failure, n (%)† | 1 (3.1) | 24 (17.4) |
AlloSCT, allogeneic stem cell transplantation; BTKi, Bruton’s tyrosine kinase inhibitor; chemo, chemotherapy; CPI, immune checkpoint inhibitors; IMiDs, immunomodulatory drugs; RT, radiotherapy.
Four patients with HGBL and 35 patients with DLBCL who relapsed following CAR T-cell therapy were excluded from the analysis due to incomplete data on disease characteristics at relapse, precluding their inclusion in multivariate models.
All values were calculated on the population of patients who received a treatment.